MedTrace Logo

MSC303 Subcutaneous Injection for the Treatment of Immunologic Glomerular Disease.

NCT07000292 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2025-06-11

No results posted yet for this study

Summary

This study will evaluate the safety and efficacy of MSC303 in patients with Immune glomerular diseases.

Conditions

  • Lupus Nephritis (LN)
  • ANCA-Associated Glomerulonephritis

Interventions

DRUG

Injection of MSC303

Dose Group 1: D1, D8, D15, and D36 were respectively given 1, 5, 15, and 15 mg of MSC303 for injection; The second dose group: D1, D8, D15 and D36 were respectively given for injection MSC303 1, 5, 20, 20 mg.

Sponsors & Collaborators

  • Shanghai Changzheng Hospital

    lead OTHER

Principal Investigators

  • Huji Xu, Ph.D, MD · Shanghai Changzheng Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-20
Primary Completion
2026-05-20
Completion
2027-02-20

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07000292 on ClinicalTrials.gov